Interstitial Lung Disease (ILD) Antibody Test Panel

ANTIGENS / BIOMARKERS

Anti-CENP A+B, Topo‐I/Scl‐70, RNA polymerase III, fibrillarin, Th/To/hPOP1, Ku, PDGFR, Ro52/TRIM21, PM/Scl-75, PM/Scl-100, Nor90/Hubf, Jo‐1, Mi2, Mi2‐α, Mi2β, MDA5, NXP2, TIF1γ, PL7, PL12, Ku, SRP, EJ, OJ

TURNAROUND-TIME (TAT)

5-7 Days

SKU / TEST CODE

ILD

PROCEDURE / TECHNIQUE

Addressable LASER Bead Immunoassay (ALBIA)

REFERENCE RANGE

Qualitative (SI :Signal Intensity) • Negative <10 SI • Weak Positive 11-29 SI • Medium Positive 30-89 SI • High positive >90 SI

SENSITIVITY / SPECIFICITY

TBD

CLINICAL ASSOCIATIONS

Mitogen’s Interstitial Lung Disease (ILD) Antibody Profile is an autoimmune diagnostic test that detects antibodies directed to Jo-1 (histidyl t-RNA synthetase) and other synthetase targets (PL7, PL-12, OJ, EJ); as well as Ku, Scl-70- (topoisomerase I), CENP-B, Scl-34 (fibrillarin), Th/To, RNA polymerase, U1-RNP, Ro52/TRIM21, Mi-2, MDA-5. Autoantibodies directed to these targets have been associated with the presence or risk of developing interstitial lung disease (ILD), or a risk of developing a systemic rheumatic disease.

Reference: BR Stevenson, Pathology 51: 518, 2019.